Optimizing Drug Pipelines With Biophysical Methods
Sponsored by:
Sponsored by:
More from R&D
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
More from Scrip
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.
Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.